Avalyn Pharma Inc. Net Fee Amt
Avalyn Pharma Inc. (AVLN) had Net Fee Amt of $13.91 thousand as of 2026-04-29, per its S-1/A filed 2026-04-29.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-30
- 2026-04-29: Net Fee Amt $13.91K.
- 2026-04-28: Net Fee Amt $14.27K.
- 2026-04-20: Net Fee Amt $19.92K.
- 2026-04-03: Net Fee Amt $13.81K.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-29 | $13.91K S-1/A · filed 2026-04-29 |
| 2026-04-28 | $14.27K S-8 · filed 2026-04-30 |
| 2026-04-20 | $19.92K S-1/A · filed 2026-04-23 |
| 2026-04-03 | $13.81K S-1 · filed 2026-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |